These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 33213862)
1. Multifunctional tumor-targeted PLGA nanoparticles delivering Pt(IV)/siBIRC5 for US/MRI imaging and overcoming ovarian cancer resistance. Zhang Y; Dong Y; Fu H; Huang H; Wu Z; Zhao M; Yang X; Guo Q; Duan Y; Sun Y Biomaterials; 2021 Feb; 269():120478. PubMed ID: 33213862 [TBL] [Abstract][Full Text] [Related]
2. GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer. Huang H; Dong Y; Zhang Y; Ru D; Wu Z; Zhang J; Shen M; Duan Y; Sun Y Theranostics; 2019; 9(4):1047-1065. PubMed ID: 30867815 [No Abstract] [Full Text] [Related]
3. Dual-mode US/MRI nanoparticles delivering siRNA and Pt(iv) for ovarian cancer treatment. Zhang Y; Huang H; Fu H; Zhao M; Wu Z; Dong Y; Li H; Duan Y; Sun Y RSC Adv; 2019 Oct; 9(57):33302-33309. PubMed ID: 35529112 [TBL] [Abstract][Full Text] [Related]
4. Prevention of Oxidized Low Density Lipoprotein-Induced Endothelial Cell Injury by DA-PLGA-PEG-cRGD Nanoparticles Combined with Ultrasound. Li Z; Huang H; Huang L; Du L; Sun Y; Duan Y Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28406431 [TBL] [Abstract][Full Text] [Related]
5. Ultrasound and magnetic resonance imaging of cyclic arginine glycine aspartic acid-gadopentetic acid-polylactic acid in human breast cancer by targeting αvβ3 in xenograft-bearing nude mice. Fu D; Huang X; Lv Z; Zhang Y; Chen M; Zhang W; Su D Bioengineered; 2022 Mar; 13(3):7105-7117. PubMed ID: 35259049 [TBL] [Abstract][Full Text] [Related]
6. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy. Yang GG; Pan ZY; Zhang DY; Cao Q; Ji LN; Mao ZW ACS Appl Mater Interfaces; 2020 Sep; 12(39):43444-43455. PubMed ID: 32883070 [TBL] [Abstract][Full Text] [Related]
7. Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer. Wang Y; Luo Z; Zhou D; Wang X; Chen J; Gong S; Yu Z Biomater Sci; 2021 Jun; 9(11):4110-4119. PubMed ID: 33949442 [TBL] [Abstract][Full Text] [Related]
8. cRGD-targeted heparin nanoparticles for effective dual drug treatment of cisplatin-resistant ovarian cancer. Liang X; Yang Y; Huang C; Ye Z; Lai W; Luo J; Li X; Yi X; Fan JB; Wang Y; Wang Y J Control Release; 2023 Apr; 356():691-701. PubMed ID: 36933699 [TBL] [Abstract][Full Text] [Related]
9. Novel Nano-Therapeutic Approach Actively Targets Human Ovarian Cancer Stem Cells after Xenograft into Nude Mice. Abou-ElNaga A; Mutawa G; El-Sherbiny IM; Abd-ElGhaffar H; Allam AA; Ajarem J; Mousa SA Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28417924 [TBL] [Abstract][Full Text] [Related]
10. Multimodal and multifunctional nanoparticles with platelet targeting ability and phase transition efficiency for the molecular imaging and thrombolysis of coronary microthrombi. Bai S; Liao J; Zhang B; Zhao M; You B; Li P; Ran H; Wang Z; Shi R; Zhang G Biomater Sci; 2020 Sep; 8(18):5047-5060. PubMed ID: 32830839 [TBL] [Abstract][Full Text] [Related]
11. (cRGD)2 peptides modified nanoparticles increase tumor-targeting therapeutic effects by co-delivery of albendazole and iodine-131. Liu S; Liu H; Sun H; Deng S; Yue L; Weng Z; Yang J; Zuo B; He Y; Zhang B Anticancer Drugs; 2022 Jan; 33(1):19-29. PubMed ID: 34261920 [TBL] [Abstract][Full Text] [Related]
12. Zwitterionic nanoparticles constructed from bioreducible RAFT-ROP double head agent for shell shedding triggered intracellular drug delivery. Huang P; Liu J; Wang W; Zhang Y; Zhao F; Kong D; Liu J; Dong A Acta Biomater; 2016 Aug; 40():263-272. PubMed ID: 26607767 [TBL] [Abstract][Full Text] [Related]
13. Altered Cell Cycle Arrest by Multifunctional Drug-Loaded Enzymatically-Triggered Nanoparticles. Huang C; Sun Y; Shen M; Zhang X; Gao P; Duan Y ACS Appl Mater Interfaces; 2016 Jan; 8(2):1360-70. PubMed ID: 26698111 [TBL] [Abstract][Full Text] [Related]
14. cRGD-functionalized nanoparticles for combination therapy of anti-endothelium dependent vessels and anti-vasculogenic mimicry to inhibit the proliferation of ovarian cancer. Wang Y; Tong L; Wang J; Luo J; Tang J; Zhong L; Xiao Q; Niu W; Li J; Zhu J; Chen H; Li X; Wang Y Acta Biomater; 2019 Aug; 94():495-504. PubMed ID: 31252171 [TBL] [Abstract][Full Text] [Related]
15. Carboplatin prodrug conjugated Fe Song H; Quan F; Yu Z; Zheng M; Ma Y; Xiao H; Ding F J Mater Chem B; 2019 Jan; 7(3):433-442. PubMed ID: 32254730 [TBL] [Abstract][Full Text] [Related]
16. The therapeutic effect and MR molecular imaging of FA-PEG-FePt/DDP nanoliposomes in AMF on ovarian cancer. Bian X; Guo T; Chen G; Nie D; Yue M; Zhu Y; Lin M Int J Nanomedicine; 2024; 19():5227-5243. PubMed ID: 38855734 [TBL] [Abstract][Full Text] [Related]
17. Encapsulation of crocetin into poly (lactic-co-glycolic acid) nanoparticles overcomes drug resistance in human ovarian cisplatin-resistant carcinoma cell line (A2780-RCIS). Neyshaburinezhad N; Kalalinia F; Hashemi M Mol Biol Rep; 2019 Dec; 46(6):6525-6532. PubMed ID: 31646427 [TBL] [Abstract][Full Text] [Related]
18. A multifunctional-targeted nanoagent for dual-mode image-guided therapeutic effects on ovarian cancer cells. Chen C; Sun J; Chen S; Liu Y; Zhu S; Wang Z; Chang S Int J Nanomedicine; 2019; 14():753-769. PubMed ID: 30718954 [TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Dhar S; Gu FX; Langer R; Farokhzad OC; Lippard SJ Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17356-61. PubMed ID: 18978032 [TBL] [Abstract][Full Text] [Related]
20. Glutathione-Scavenging Poly(disulfide amide) Nanoparticles for the Effective Delivery of Pt(IV) Prodrugs and Reversal of Cisplatin Resistance. Ling X; Chen X; Riddell IA; Tao W; Wang J; Hollett G; Lippard SJ; Farokhzad OC; Shi J; Wu J Nano Lett; 2018 Jul; 18(7):4618-4625. PubMed ID: 29902013 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]